Drug Trial Radar · NCT06278207
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50,000
Planned (sponsor's estimate)
Start
May 15, 2024
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems. The researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone. The data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests in this study.
Conditions
- Chronic Kidney Disease
- Type 2 Diabetes Mellitus
Interventions
Finerenone (BAY 94-8862)Drug
10 mg or 20 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone.Time frame: 12 months before first prescription/dispensation of finerenone (index date)
- Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone.Time frame: 12 months before first prescription/dispensation of finerenone (index date)
- Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone.Time frame: 12 months before first prescription/dispensation of finerenone (index date)
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Many Locations
Many Locations, New Jersey · Completed
Bayer
Berlin, Germany · Recruiting
Many Locations
Many Locations, Japan · Completed
Many Locations
Many Locations, Taiwan · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.